EVOLVE-1: Advanced Hepatocellular Carcinoma After Disease Progression or Intolerance to Sorafenib
EVOLVE-1 (EVerOlimus for LiVer cancer Evaluation-1) is a phase III, randomized, double-blind study of everolimus in advanced hepatocellular carcinoma after failure of sorafenib therapy.
Patients are randomized to receive either everolimus (RAD001) 7.5 mg/day orally or placebo, plus best supportive care. This global clinical trial will enroll 531 patients with HCC in a 2:1 randomization to everolimus or placebo, at more than 100 sites. Patients may have received 1 prior systemic chemotherapy regimen for advanced HCC, providing sorafenib was the last antineoplastic treatment prior to entering the study.
Click here to learn more about this clinical trial and participating centers from ClinicalTrials.gov.
Disclaimer : These are investigational studies; there is no guarantee that everolimus will become commercially available for these indications
Disclaimer : This is a global web site for the The WIDE Program™ providing general information for healthcare professionals from all countries. The information on this site is not country-specific and may contain program information that is different from where you practice. Please contact your local Novartis representative for the latest information specific to your country.
